BioCentury
ARTICLE | Company News

Antisoma, Transgene deal

December 21, 1998 8:00 AM UTC

TRGNY acquired an exclusive license to Antisoma's technology for targeting modified adenoviral vectors to specific cellular targets. TRGNY also has an option to obtain exclusive licenses from Antisoma...